Berenberg raises Merck stock price target on cancer drug data

Berenberg raised Merck's price target to $137 from $127 but retained a Hold rating, arguing that the shares' 40% year-to-date gain and 75.6% one-year return have left valuation full. The firm estimates $16 billion in peak sales for intismeran and increased its NPV estimate by $12 billion, versus a $42 billion rise in Merck's market capitalization after positive Phase 3 melanoma data. Analyst views remain divided, with Guggenheim and Wolfe setting targets of $170 and $180, respectively, while UBS downgraded the stock to Neutral with a $150 target.

Analysis

MRK’s rerating increasingly embeds a successful replacement for Keytruda rather than merely incremental oncology optionality. The relevant underwriting question is not headline peak sales but Merck’s post-partnership economics, launch timing, manufacturing cost, and whether new regimens extend treatment duration or cannibalize existing Keytruda revenue. With the stock already pricing a meaningful portion of pipeline de-risking, future upside requires evidence of broad, durable benefit across large tumor settings—not another favorable subset readout.

MRNA is the higher-beta expression of the same clinical thesis, but its valuation recovery will depend on whether oncology can offset the steep decline in COVID franchise cash flows before commercial-scale launches. Positive data can lift both names in days, yet MRK should retain more downside protection from its base business while MRNA remains exposed to financing, burn-rate, and platform-validation risk over the next 12-24 months. A weaker-than-expected remigromig result would matter disproportionately for MRK because it would reinforce the market’s concern that pipeline breadth is narrower than the oncology narrative implies.

Consensus may be underestimating competitive and reimbursement friction: personalized cancer vaccines require tumor sampling, sequencing, manufacturing, and coordination with infusion schedules. Even compelling efficacy may translate into slower initial penetration and lower gross margins than a conventional biologic. Conversely, if real-world turnaround times and discontinuation rates are favorable, the platform could create a defensible oncology ecosystem that benefits MRNA more than current near-term revenue models imply.

Key Decisions for Investors

• Do not add outright MRK exposure ahead of the next major pipeline readout after the sharp rerating; use a 1-3 month watch for a pullback or evidence that forward earnings estimates are rising faster than the share price. Thesis is falsified if management cannot articulate post-Keytruda revenue durability or if pivotal data fail to demonstrate clinically meaningful durability.
• Consider a 6-12 month pair: long MRK / short MRNA in equal beta-adjusted dollars for investors seeking exposure to oncology-vaccine validation with lower execution risk. MRK has diversified cash generation, while MRNA bears the larger commercialization and cash-burn burden; close the spread if MRNA provides credible launch economics, manufacturing turnaround metrics, and materially improves its medium-term revenue outlook.
• For bullish platform exposure, prefer a defined-risk MRNA call spread dated beyond the next key clinical/regulatory catalyst rather than common equity. This captures asymmetric upside from cross-indication validation while limiting loss if oncology timelines slip; avoid sizing until trial endpoint details, addressable population, and partnership economics are independently verified.
• Monitor MRK implied volatility and relative performance versus XLV through upcoming data events. A positive read with MRK lagging XLV would indicate that upside is already capitalized; a negative read accompanied by a limited MRK drawdown would support the view that the base franchise—not pipeline optionality—is the appropriate reason to own the shares.